Company: G
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001398659-25-000059
Chunk: 90

Company: Genpact LTD
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 90
---
 on the revaluation of foreign currency assets/liabilities in the three months ended March 31, 2025 compared to the three months ended March 31, 2024. This increase was partially offset by a decrease in the allowance for credit losses and deferred tax expense in the three months ended March 31, 2025 compared to the three months ended March 31, 2024.

Cash flows used for/provided by investing activities. Our net cash provided by investing activities was $0.8 million in the three months ended March 31, 2025 compared to net cash used for investing activities of $24.7 million in the three months ended March 31, 2024. Net cash provided by investing activities increased primarily due to the maturity of $23.4 million in term deposits in the three months ended March 31, 2025 compared to no proceeds from investments in the three months ended March 31, 2024.  Cash used for payments (net of sales proceeds) for the purchase of property, plant and equipment and internally generated intangible assets in the three months ended March 31, 2025 was $2.1 million lower than in the three months ended March 31, 2024.

53

Cash flows used for financing activities. Our net cash used by financing activities was $125.5 million in the three months ended March 31, 2025 compared to $48.2 million in the three months ended March 31, 2024. This change was primarily due to (i) higher payments for stock repurchased and retired (including related expenses), amounting to $63.0 million in the three months ended March 31, 2025 compared to $30.0 million in the three months ended March 31, 2024, (ii) higher repayment of borrowings (net of proceeds), amounting to $6.6 million in the three months ended March 31, 2025 compared to proceeds from borrowings (net of repayment) of $26.8 million in the three months ended March 31, 2024, and (iii) higher payments for the net settlement of stock-based awards, amounting to $30.7 million in the three months ended March 31, 2025 compared to $20.8 million in the three months ended March 31, 2024.

Financing Arrangements

In December 2022, we entered into an amended and restated credit agreement (